The authors trained two attention-based multiple-instance learning models on digitized routine hematoxylin and eosin whole-slide images. One model, HERA, was built to predict binary HPV/p16 status. The second model, HERMES, was trained to assign one of three molecular subtypes: HPV-associated, HPV-independent/p53-wildtype, and HPV-independent/p53-abnormal. Feature extraction used the H-optimus-1 pipeline, as reported by the study team. Model development employed slides from 644 patients pooled across three Dutch vulvar squamous cell carcinoma (VSCC) cohorts. Independent testing occurred on 286 patients from two external cohorts. The abstract does not report granular training hyperparameters, per-cohort demographics, or the full preprocessing pipeline; those details may be present in the full article or supplementary files but are not contained in the abstract.
In independent testing, the investigators reported that HERA discriminated HPV/p16 status with an area under the curve (AUC) of 0.84 (95% CI 0.75–0.91). The model achieved high specificity (0.93) and a negative predictive value of 0.94, while sensitivity was 0.68. The authors noted that HERA-predicted groups reproduced the prognostic separation obtained by HPV testing; the reported log-rank p value for survival separation was <0.001. These performance metrics suggest the model favors ruling out HPV/p16 positivity with fewer false positives, at the expense of moderate sensitivity. The abstract does not specify decision thresholds used, calibration statistics, or per-site performance stratified by scanner or cohort.
The study team reported that HERMES produced a macro-average AUC of 0.70 (0.66–0.75) in independent testing. Class-level discrimination varied: the model distinguished HPV-associated cases best (AUC 0.80), but separation between the two HPV-independent subtypes was limited (AUC 0.68 for HPV-independent/p53-abnormal and AUC 0.63 for HPV-independent/p53-wildtype). HERMES-predicted classes recapitulated a prognostic hierarchy: reported 5-year recurrence rates were 14.0% for HPV-associated tumors, 31.1% for HPV-independent/p53-wildtype tumors, and 43.3% for HPV-independent/p53-abnormal tumors (p=0.0051). The abstract does not provide confusion matrices, per-class predictive values, or misclassification patterns beyond the AUCs and recurrence outcomes.
The authors examined highly attended image tiles to interpret model focus. For HPV-associated tumors, highly attended tiles showed basaloid cells and koilocytotic-like atypia. For HPV-independent/p53-abnormal tumors, the model attended to keratinizing nests with desmoplastic stroma. For HPV-independent/p53-wildtype tumors, attended regions included well-differentiated keratinocytes with spongiosis. These observations indicate that the models leveraged recognizable morphologic features that pathologists associate with the respective molecular states. The abstract does not quantify the frequency of these patterns or provide per-tile attention score distributions; such details, if collected, appear outside the abstract text.
The study team proposed that HERA could assign HPV/p16 status to large retrospective VSCC cohorts lacking ancillary immunohistochemistry, without consuming additional tissue. That capability would enable HPV-stratified outcome analyses in archival series where p16 or HPV testing is incomplete or unavailable. The authors explicitly caution that use for cohort annotation requires external validation of both discrimination and calibration across different scanners and populations before implementation. The abstract does not assert immediate clinical application; instead, it frames tissue-sparing assignment as a potential research tool pending validation.
The authors acknowledged limitations in subtype discrimination: HERMES showed only limited separation between the two HPV-independent molecular subtypes, indicating the need for model improvement. The abstract calls for external validation of discrimination and calibration across scanners and populations as a prerequisite for broader use. The abstract does not list other potential limitations such as sample selection biases, slide quality variability, or the impact of pre-analytic factors; those may be discussed in the full manuscript. Key unanswered questions documented in the abstract include whether performance generalizes across hardware and diverse patient populations, and how to improve distinction between the HPV-independent subtypes prior to any application in clinical practice or retrospective cohort annotation.